Tagged with GOvernment Relations

Pharma The General Manager of LEEM talks about the association’s strategy based on three key points, innovation, attractiveness and efficiency; how the Mediator affair has placed a question mark on the championing of the pharma industry as a national asset; why both France and Europe are at turning point and what…

Pharma Michel Dutree, former director general of the Dutch association for pharmaceutical innovators, gives a detailed overview of the changes happening in the Dutch pharmaceutical industry, and the Netherlands’ role at the European level as the “laboratory of Europe.” It’s been four years since your last interview with PBR; what do…

Pharma Centre International de Développement Pharmaceutique (CIDP) has pioneered cosmetic and pharmaceutical Research & Development in Mauritius, and is Mauritius’ flagship success story in the sector. Founded over 10 years ago, CIDP is an international CRO (Contract Research Organisation). As an entrepreneur and a pioneer, which opportunities did you see in Mauritius that…

Pharma Colette Alma-Zeestraten tells PharmaBoardroom about how the Dutch Pharma Industry is adapting, how it is making use of clusters to become more competitive, energy efficient, and innovative, and how the nine billion euro contribution the pharmaceuticals sector makes to the Dutch chemicals industry. Over your last 10 years at the VNCI, what…

Turkey Over the past six years, Turkey has consistently lowered its drugs prices and guided its companies to greater efficiency. “Reference prices in Turkey are constructed from the lowest price in France, Greece, Italy, Spain or Portugal, converted to Turkish Lira at a rate of TRY 1.9595 per EUR,” says Cem…

Turkey In the coming years, Turkey plans to prioritize R&D initiatives, health studies and medical innovation: that’s the core message Minister of Health Mehmet Müezzinoğlu gave PharmaBoardroom. This is the beginning of a new era for healthcare in Turkey. The twenty-first century has already been a period of change in the…

research AM Pharma is developing an innovative treatment for acute kidney injury, and minority investor Pfizer recently acquired the option to purchase the firms remaining equity upon the completion of a phase II clinical trial. How competitive do you feel Dutch life sciences in the academic setting are amongst your other…

healthcare Nefarma’s healthcare policy advisor discusses the changes in the Dutch reimbursement system over the previous five years, and the need for greater trust between different healthcare stakeholders to allow effective collaboration and negotiation. How has the pharmaceutical reimbursement system in the Netherlands changed over the last few years? To start…

Holland In a market under strong pressures to contain costs, launching innovative products in a crowded market can be a challenge. Novo Nordisk GM Sanne Groenemeijer believes his organization’s willingness to try various solutions has helped them to maintain their dominant position as the market leader in diabetes. Since you took…

manufacturing The chancellor of the Medical Sciences Campus of the University of Puerto Rico discusses the medical R&D projects the university is currently involved in, the fields in which the island has the most potential, and how the institution is tailoring its academic offer to suit the local needs of the…

Puerto Rico Puerto Rico’s healthcare insurance market is the first in Latin America in terms of penetration and sixth in terms of premium volume. Ángela Weyne, Insurance Commissioner of Puerto Rico, discusses how recent amendments to the Affordable Care Act (ACA) have been implemented locally, how she is spurring healthy competition among…

Puerto Rico Verónica Cruz, PhD, executive vice president and COO of Puerto Rican consultancy ReComS Group, discusses the need to bring investments in the life science industry back to Puerto Rico while focusing on the country’s manufacturing strengths as a competitive advantage. What are the main challenges which ReComS is facing? Today…